Program
Aminolevulinic Acid
Also written as “Aminolevulinic Acid (ALA)”, “5 Aminolevulinic Acid” and “PD P 506 A”.
Its studies are mostly in Keratosis, Actinic · Glioma · Glioblastoma · Breast Neoplasms · Malaria, led by 10 companies.
Drug pageAminolevulinic Acid: every studyMany companies study it; this page follows only the 22 they lead. All 114 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industriesits history only | 100 open or running | phase 3since May 7, 2014 | Jun 24, 2008 | none ahead |
| Alpheus Medicalits history only | 21 open or running | phase 1since May 2, 2022 | May 2, 2022 | Oct 30, 2027phase 1 · NCT07862647 |
| medacits history only | 20 open or running | phase 3since Oct 18, 2005 | Oct 18, 2005 | none ahead |
| photonamic GmbH & Co. KGits history only | 20 open or running | phase 2since Jul 11, 2018 | Jul 11, 2018 | none ahead |
| Hemerion Therapeuticsits history only | 11 open or running | phase 2since Feb 8, 2023 | Feb 8, 2023 | none ahead |
| Lee's Pharmaceuticalits history only | 11 open or running | phase 3since Nov 27, 2023 | Nov 27, 2023 | Dec 2027phase 3 · NCT06160492 |
| Neopharma Japanits history only | 10 open or running | phase 2since Jul 12, 2019 | Jul 12, 2019 | none ahead |
| Nobelpharmaits history only | 10 open or running | phase 3since Jul 16, 2010 | Jul 16, 2010 | none ahead |
| SBI ALApharma Canadaits history only | 10 open or running | phase 3since Mar 22, 2021 | Mar 22, 2021 | none ahead |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceuticalits history only | 10 open or running | phase 3since May 12, 2024 | May 12, 2024 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Oct 18, 2005.
- Oct 30, 2014Phase 2 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT02281136 · 29 enrolled · United States
- Jan 22, 2015Phase 2 study in Onychomycosismedac · NCT02355899 · 25 enrolled · Germany
- Dec 7, 20152 phase 2 studies in Keratosis, ActinicSun Pharmaceutical Industries · NCT02628236, NCT02632110
- Dec 9, 2015Named aminolevulinic acidINNProposed as its International Nonproprietary Name in WHO's List 114
- Jan 13, 2017Phase 3 study in Keratosis, ActinicSun Pharmaceutical Industries · NCT03024060 · United States
- Jul 11, 2018photonamic GmbH & Co. KG’s first study: phase 2 study in Keratosis, ActinicNew to photonamic GmbH & Co. KGphotonamic GmbH & Co. KG · NCT03606122 · 22 enrolled · Germany
- Mar 19, 2019Phase 2 study in Glioblastomaphotonamic GmbH & Co. KG · NCT03897491 · 17 enrolled · Germany
- Jul 12, 2019Neopharma Japan’s first study: phase 2 study in MalariaNew to Neopharma JapanNeopharma Japan · NCT04020653
- Mar 22, 2021SBI ALApharma Canada’s first study: phase 3 study in Breast NeoplasmsNew to SBI ALApharma CanadaSBI ALApharma Canada · NCT04815083 · 57 enrolled · United States
- May 2, 2022Alpheus Medical’s first study: phase 1 study in GliomaNew to Alpheus MedicalAlpheus Medical · NCT05362409 · 22 enrolled · United States
- Feb 8, 2023Hemerion Therapeutics’ first study: phase 2 study in GliomaNew to Hemerion TherapeuticsHemerion Therapeutics · NCT05736406 · 12 enrolled · United States, France
- Nov 27, 2023Lee's Pharmaceutical’s first study: phase 3 study in GliomaNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT06160492 · 79 planned · China
- May 12, 2024Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s first study: phase 3 study in 5-aminolevulinic AcidNew to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalShanghai Fudan-Zhangjiang Bio-Pharmaceutical · NCT06417281 · 86 enrolled · China
- Sep 28, 2026Phase 1 study in GlioblastomaAlpheus Medical · NCT07862647 · 30 planned · United States
- Oct 27, 2026Primary completion moved from 2026-02 to 2027-12Date moved laterphase 3 · +22 months · NCT06160492
Ahead
- Oct 30, 2027Primary completion: phase 1 study in GlioblastomaAlpheus Medical · NCT07862647
- Dec 2027Primary completion: phase 3 study in GliomaLee's Pharmaceutical · NCT06160492
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07862647Glioblastoma · United States | 1 | Recruiting | Alpheus Medical | Oct 30, 2027 | 30 |
| NCT064172815-aminolevulinic Acid · China | 3 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Aug 19, 2025 | 86 |
| NCT06160492Glioma · China | 3 | Recruiting | Lee's Pharmaceutical | Dec 2027 | 79 |
| NCT05736406Glioma · United States, France | 2 | Active, not recruiting | Hemerion Therapeutics | Mar 6, 2026 | 12 |
| NCT05362409Glioma · United States | 1 | Completed | Alpheus Medical | Dec 3, 2024 | 22 |
| NCT04815083Breast Neoplasms · United States | 3 | Terminated | SBI ALApharma Canada | Oct 22, 2024 | 57 |
| NCT04020653Malaria | 2 | Withdrawn | Neopharma Japan | May 31, 2020 | 0 |
| NCT03897491Glioblastoma · Germany | 2 | Terminated | photonamic GmbH & Co. KG | Apr 8, 2026 | 17 |
| NCT03606122Keratosis, Actinic · Germany | 2 | Completed | photonamic GmbH & Co. KG | Jul 16, 2019 | 22 |
| NCT03024060Keratosis, Actinic · United States | 3 | Withdrawn | Sun Pharmaceutical Industries | Sep 2017 | 0 |
| NCT02632110Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Sep 12, 2016 | 137 |
| NCT02628236Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | May 2016 | 14 |
| NCT02355899Onychomycosis · Germany | 2 | Completed | medac | Aug 23, 2017 | 25 |
| NCT02281136Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Apr 2015 | 29 |
| NCT02239679Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Jul 2016 | 166 |
| NCT02137785Keratosis, Actinic · United States | 3 | Completed | Sun Pharmaceutical Industries | Mar 2015 | 269 |
| NCT01475955Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Nov 2012 | 235 |
| NCT01458587Keratosis, Actinic · United States | 2 | Completed | Sun Pharmaceutical Industries | Jul 2012 | 70 |
| NCT01167322Glioma · Japan | 3 | Completed | Nobelpharma | Dec 2011 | 45 |
| NCT00865878Keratosis, Actinic · United States | 2 | Terminated | Sun Pharmaceutical Industries | Sep 2011 | 6 |
| NCT00706433Acne Vulgaris · United States | 2 | Completed | Sun Pharmaceutical Industries | Jul 2008 | 266 |
| NCT00241670Brain Neoplasms | 3 | Completed | medac | Jul 2004 | 415 |
How it is read
Names in the registry
- “Aminolevulinic Acid (ALA)”, 3 entries
- “5 Aminolevulinic Acid”, 2 entries
- “PD P 506 A”, 2 entries
- “Aminolevulinic Acid”, 2 entries
- “ALA”, 2 entries
Conditions, from the studies’ own filings
- Keratosis, Actinic, 10 studies
- Glioma, 3 studies
- Glioblastoma, 3 studies
- Breast Neoplasms, 1 study
- Malaria, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.